Drug Approval | June 27, 2025
Biocon Biologics receives Health Canada approval for Yesafili
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The transaction is expected to close in Q2 FY 2026
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Now approved for both acute and chronic HCV in adults and children aged 3 and above
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Subscribe To Our Newsletter & Stay Updated
